Breakthroughs in Hepatocellular Carcinoma Therapies

Article Oncology

Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial

Shukui Qin et al.

Summary: Pembrolizumab significantly prolonged overall survival and progression-free survival in previously treated advanced hepatocellular carcinoma patients from Asia, with a higher objective response rate compared to placebo.

JOURNAL OF CLINICAL ONCOLOGY (2023)

添加到收藏夹

Article Oncology

TACE versus TARE for patients with hepatocellular carcinoma: Overall and individual patient level meta analysis

Andrew M. Brown et al.

Summary: This study conducted an overall and individual patient data (IPD) meta-analysis of transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) for the treatment of hepatocellular carcinoma (HCC). The results showed that TARE had a significantly longer time to progression (TTP) compared to TACE, but there was no significant difference in overall survival (OS) between the two modalities. The limitations of the current data include inconsistent length of follow-up and response criteria. Therefore, prospective studies comparing these treatments are needed.

CANCER MEDICINE (2023)

添加到收藏夹

Review Oncology

NASH and Hepatocellular Carcinoma: Immunology and Immunotherapy

Matthias Pinter et al.

Summary: The past 10 years have brought about a revolution in our understanding of nonalcoholic fatty liver disease (NAFLD) and liver cancer. It has been discovered that various immune cells have a significant role in initiating and exacerbating nonalcoholic steatohepatitis (NASH), a newly defined autoaggressive disease. NASH is expected to become a leading cause of hepatocellular carcinoma (HCC) despite improved disease management. The effectiveness of immunotherapy in NASH-related HCC may be diminished compared to viral HCC, but further evidence is needed to support clinical translation of these findings.

CLINICAL CANCER RESEARCH (2023)

添加到收藏夹

Editorial Material Gastroenterology & Hepatology

Radiological endpoints as surrogates for survival benefit in hepatocellular carcinoma trials: All that glitters is not gold

Giuseppe Cabibbo et al.

JOURNAL OF HEPATOLOGY (2023)

添加到收藏夹

Review Gastroenterology & Hepatology

Conceptual Model for the Hepatocellular Carcinoma Screening Continuum: Current Status and Research Agenda

Amit G. Singal et al.

Summary: Hepatocellular carcinoma (HCC) has a poor prognosis with survival rates below 20% in 5 years, partly due to failures in the cancer screening process continuum. A conceptual model outlining discrete steps in the HCC screening process highlights delays or failures at each step and identifies factors contributing to these failures at the patient, provider, and health care system levels. Comparing HCC screening processes with breast and colorectal cancer screening can help identify opportunities for improvement and ultimately improve early detection of HCC.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Baveno VII - Renewing consensus in portal hypertension

Roberto de Franchis et al.

Summary: The Baveno VII workshop focused on personalized care for portal hypertension in patients with compensated cirrhosis or cACLD, discussing various aspects including diagnosis, treatment, and prevention measures in 9 main topics, resulting in a series of consensus recommendations.

JOURNAL OF HEPATOLOGY (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: A meta-analysis

Amit G. Singal et al.

Summary: In this systematic review and meta-analysis, HCC surveillance was found to be associated with improved early-stage detection, curative treatment receipt, and survival in patients with cirrhosis. However, there was significant heterogeneity in the pooled estimates, and there were fewer data quantifying potential surveillance-related harms. Available data suggest that HCC surveillance is of high value in patients with cirrhosis, although further studies evaluating benefits and harms are still needed.

JOURNAL OF HEPATOLOGY (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma

Ann-Lii Cheng et al.

Summary: The study demonstrated that atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma patients led to improved survival outcomes. After updated analysis, atezolizumab plus bevacizumab maintained its position as the first-line treatment option for advanced hepatocellular carcinoma.

JOURNAL OF HEPATOLOGY (2022)

添加到收藏夹

Article Oncology

Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial

Thomas Yau et al.

Summary: First-line nivolumab treatment did not significantly improve overall survival compared with sorafenib in patients with advanced hepatocellular carcinoma, but clinical activity and a favorable safety profile were observed in some patients.

LANCET ONCOLOGY (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis

Victor Sapena et al.

Summary: This meta-analysis assessed the risk of HCC recurrence following DAA administration in HCV-related cirrhosis and HCC patients. Results showed an increased risk of recurrence and death in patients treated with DAAs, but no significant difference was observed in comparison to the DAA-unexposed group. Factors influencing recurrence included alpha-fetoprotein levels, pre-DAA recurrence history, patient performance status, and tumor burden.

GUT (2022)

添加到收藏夹

Article Oncology

Final Results of TACTICS: A Randomized, Prospective Trial Comparing Transarterial Chemoembolization Plus Sorafenib to Transarteria Chemoembolization Alone in Patients with Unresectable Hepatocellular Carcinoma

Masatoshi Kudo et al.

Summary: The final OS analysis from the TACTICS trial demonstrated no significant OS benefit of TACE plus sorafenib compared to TACE alone in patients with HCC. However, there was a clinically meaningful OS prolongation and significantly improved PFS. Therefore, TACE plus sorafenib can be considered as a treatment option for intermediate-stage HCC, especially in patients with high tumor burden.

LIVER CANCER (2022)

添加到收藏夹

Article Oncology

Surgery versus Radiofrequency Ablation for Small Hepatocellular Carcinoma: A Randomized Controlled Trial (SURF Trail)

Tadatoshi Takayama et al.

Summary: This study compared the survival rates of surgery and RFA for small HCC and found no significant difference between the two treatments.

LIVER CANCER (2022)

添加到收藏夹

Article Oncology

External Beam Radiation Therapy for Primary Liver Cancers: An ASTRO Clinical Practice Guideline

Smith Apisarnthanarax et al.

Summary: This guideline provides evidence-based recommendations for external beam radiation therapy in hepatocellular carcinoma and intrahepatic cholangiocarcinoma, covering indications, techniques, outcomes, and emphasizing multidisciplinary care. Future studies should focus on defining the role of EBRT in the context of liver directed and systemic therapies.

PRACTICAL RADIATION ONCOLOGY (2022)

添加到收藏夹

Review Gastroenterology & Hepatology

BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update

Maria Reig et al.

Summary: There have been significant advances in the treatment strategies for hepatocellular carcinoma since the last update in 2018. However, some interventions still lack sufficient data for clinical incorporation, and personalized clinical management requires consideration of multiple parameters.

JOURNAL OF HEPATOLOGY (2022)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

90Y Radioembolization versus Drug-eluting Bead Chemoembolization for Unresectable Hepatocellular Carcinoma: Results from the TRACE Phase II Randomized Controlled Trial

Elisabeth Dhondt et al.

Summary: This study compared the efficacy and safety of Y-90 glass TARE and DEB-TACE for unresectable HCC. The results showed that TARE conferred superior tumor control and overall survival compared to DEB-TACE. Both treatments had similar safety profiles.

RADIOLOGY (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial

Ahmed Omar Kaseb et al.

Summary: This study aimed to evaluate the safety and tolerability of perioperative immunotherapy in patients with resectable hepatocellular carcinoma. The findings suggest that nivolumab alone or in combination with ipilimumab is safe and feasible in this patient population, supporting further studies of immunotherapy in the perioperative setting for hepatocellular carcinoma.

LANCET GASTROENTEROLOGY & HEPATOLOGY (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Radiation segmentectomy for curative intent of unresectable very early to early stage hepatocellular carcinoma (RASER): a single-centre, single-arm study

Edward Kim et al.

Summary: Radiation segmentectomy is a safe and effective treatment option for unresectable hepatocellular carcinoma with suboptimal location for ablation, with a low proportion of high-grade adverse events. Further investigation is warranted to explore its potential as a curative treatment option.

LANCET GASTROENTEROLOGY & HEPATOLOGY (2022)

添加到收藏夹

Review Gastroenterology & Hepatology

Hepatocellular carcinoma downstaging for liver transplantation in the era of systemic combined therapy with anti-VEGF/TKI and immunotherapy

Nguyen H. Tran et al.

Summary: Hepatocellular carcinoma is a global health challenge, and liver transplantation is the best long-term treatment option. Locoregional methods for downstaging have limitations, while systemic treatments show potential for downstaging before transplantation. Assessment, endpoints, and clinical trial designs are critical considerations.

HEPATOLOGY (2022)

添加到收藏夹

Article Oncology

Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312) : a multicentre, open-label, randomised, phase 3 trial

Robin Kate Kelley et al.

Summary: This study evaluated the combination of cabozantinib and atezolizumab versus sorafenib as first-line systemic treatment for advanced hepatocellular carcinoma. The combination treatment group showed better progression-free survival compared to the sorafenib group, but overall survival did not reach statistical significance. Common adverse events in the combination group included liver enzyme elevation, hypertension, and skin reactions. The study suggests that cabozantinib plus atezolizumab may be a treatment option, but further research is needed.

LANCET ONCOLOGY (2022)

添加到收藏夹

Editorial Material Oncology

Atezolizumab plus Bevacizumab Followed by Curative Conversion (ABC Conversion) in Patients with Unresectable, TACE-Unsuitable Intermediate-Stage Hepatocellular Carcinoma

Masatoshi Kudo

LIVER CANCER (2022)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

Initiative on Superselective Conventional Transarterial Chemoembolization Results (INSPIRE)

Thierry de Baere et al.

Summary: Several publications and recommendations have highlighted the benefits of superselective conventional TransArterial ChemoEmbolization (cTACE) in treating Hepatocellular Carcinoma (HCC). The use of a microcatheter positioned close to the tumor improves outcomes and minimizes collateral damage to the liver parenchyma. Experts recommend that cTACE should be superselective and performed with a 1.5-2.0 Fr microcatheter. Angio Cone-Beam Computed Tomography (CBCT) can be used to guide the procedure and assess tumor coverage.

CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Low utilization of adult-to-adult LDLT in Western countries despite excellent outcomes: International multicenter analysis of the US, the UK, and Canada

Tommy Ivanics et al.

Summary: This multicenter international comparative analysis shows that the long-term outcomes of living donor liver transplantation in the United States, the United Kingdom, and Canada are excellent, despite low utilization rates. There is no statistically significant difference in mortality risk between the evaluated countries. However, the incidence and risk of retransplantation vary between countries, with the highest in the United Kingdom and the lowest in the United States.

JOURNAL OF HEPATOLOGY (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Pathogenesis of primary liver carcinomas

Valérie Paradis et al.

JOURNAL OF HEPATOLOGY (2022)

添加到收藏夹

Review Medicine, General & Internal

Hepatocellular carcinoma

Arndt Vogel et al.

Summary: Hepatocellular carcinoma is a common cancer worldwide, with non-alcoholic fatty liver disease becoming a dominant cause. Treatment options are varied, including surgery, radiation, and medication. With the approval of new drugs and the development of immunotherapy, the outlook for hepatocellular carcinoma patients has improved, but the optimal sequencing of drugs and predictive biomarkers still need further research.

LANCET (2022)

添加到收藏夹

Review Gastroenterology & Hepatology

Local and Regional Therapies for Hepatocellular Carcinoma

Roman Kloeckner et al.

HEPATOLOGY (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Steatohepatitis Impairs T-cell-Directed Immunotherapies Against Liver Tumors in Mice

Bernd Heinrich et al.

Summary: This study found that steatohepatitis reduces infiltration of CD4(+) T cells and effector memory cells in liver tumors, which decreases the efficacy of immunotherapeutic agents like M30 and aOX40 in inhibiting tumor growth. N-acetylcysteine can restore T-cell numbers in tumors and enhance the ability of M30 and aOX40 to slow tumor growth in mice.

GASTROENTEROLOGY (2021)

添加到收藏夹

Letter Surgery

PD-1 inhibitor as bridge therapy to liver transplantation?

Parissa Tabrizian et al.

AMERICAN JOURNAL OF TRANSPLANTATION (2021)

添加到收藏夹

Review Gastroenterology & Hepatology

Role of Multidisciplinary Care in the Management of Hepatocellular Carcinoma

Kia Byrd et al.

Summary: Despite advancements in treatment options for hepatocellular carcinoma (HCC), the 5-year survival rate remains below 20%, partially due to underuse of curative treatment in clinical practice. A multidisciplinary approach involving various specialists has been evolving to develop therapeutic plans for HCC management, leading to improved timely guideline-concordant treatment and overall survival.

SEMINARS IN LIVER DISEASE (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial

Etienne Garin et al.

Summary: This study compared the efficacy of personalized versus standard dosimetry in selective internal radiation therapy for advanced hepatocellular carcinoma, showing that personalized dosimetry significantly improved the objective response rate. The results suggest that personalized dosimetry may enhance outcomes in clinical practice and should be considered for future trials.

LANCET GASTROENTEROLOGY & HEPATOLOGY (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Systemic treatment of hepatocellular carcinoma: An EASL position paper

Jordi Bruix et al.

Summary: Significant advances have been made in the systemic treatment of hepatocellular carcinoma in the last 5 years, with new drugs and treatment strategies emerging. Prolonged survival exceeding 2 years is expected in most patients, and selecting the right medication based on patient characteristics and preferences is crucial for sound therapeutic decisions.

JOURNAL OF HEPATOLOGY (2021)

添加到收藏夹

Letter Oncology

Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines

A. Vogel et al.

ANNALS OF ONCOLOGY (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

International Liver Cancer Association (ILCA) White Paper on Biomarker Development for Hepatocellular Carcinoma

Amit G. Singal et al.

GASTROENTEROLOGY (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Endpoints in clinical trials for liver cancer and their value in evidence-based clinical decision making: An unresolved Gordian knot

Jordi Bruix

Summary: Clinical trials rely on strict definitions and criteria, but real-world clinical practice may not follow the same guidelines, leading to discrepancies in patient selection, disease assessment, and treatment decisions. Understanding these differences is crucial in refining criteria for drug activity, toxicity, and treatment failure in order to achieve evidence-based clinical practice and precision oncology.

JOURNAL OF HEPATOLOGY (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Yttrium-90 Radioembolization for the Treatment of Solitary, Unresectable HCC: The LEGACY Study

Riad Salem et al.

Summary: The LEGACY study evaluated the efficacy of yttrium-90 glass microspheres in treating solitary, unresectable HCC <= 8 cm, showing promising response rates and durable responses in a multicenter setting.

HEPATOLOGY (2021)

添加到收藏夹

Article Multidisciplinary Sciences

NASH limits anti-tumour surveillance in immunotherapy-treated HCC

Dominik Pfister et al.

Summary: The study investigated the impact of NASH on immunotherapy response in HCC patients and found that NASH-HCC may be less responsive to immunotherapy. Aberrant T cell activation caused by NASH-related tissue damage led to impaired immune surveillance in HCC patients.

NATURE (2021)

添加到收藏夹

Review Gastroenterology & Hepatology

Advances in immunotherapy for hepatocellular carcinoma

Bruno Sangro et al.

Summary: Immunotherapeutic interventions have shown effectiveness in the treatment of hepatocellular carcinoma. Checkpoint inhibitors have demonstrated strong anti-tumor activity, but other immune strategies have not yet shown consistent clinical activity. Advancing treatment to earlier stages, discovering predictive biomarkers, and exploring effective combinatorial approaches are key challenges in HCC immunotherapy.

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2021)

添加到收藏夹

Article Surgery

Dynamic α-Fetoprotein Response and Outcomes After Liver Transplant for Hepatocellular Carcinoma

Karim J. Halazun et al.

Summary: This study validates the importance of AFP-R in selecting patients with HCC for liver transplant, showing its accurate prediction of recurrence and overall survival. AFP-R is a truly objective pre-transplant biological characteristic, and its incorporation into selection criteria allows for safe expansion of existing models and offers transplant opportunities to patients with acceptable tumor characteristics who might otherwise be denied potential cure.

JAMA SURGERY (2021)

添加到收藏夹

Review Oncology

Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update

Masatoshi Kudo et al.

Summary: The Clinical Practice Manual for Hepatocellular Carcinoma is based on evidence and expert consensus, focusing on pathology, diagnosis, and treatment. Different from the JSH Clinical Practice Guidelines, this manual emphasizes practicality and is written by a panel of experts from the JSH.

LIVER CANCER (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Downstaging Outcomes for Hepatocellular Carcinoma: Results From the Multicenter Evaluation of Reduction in Tumor Size before Liver Transplantation (MERITS-LT) Consortium

Neil Mehta et al.

Summary: This study is the first multiregional study based on UNOS-DS criteria, showing a successful downstaging rate of >80% and similar efficacy of chemoembolization and yttrium-90 radioembolization as the initial downstaging treatment. Despite a 2-year post-LT survival rate of 95%, a high rate of tumor understaging was observed.

GASTROENTEROLOGY (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis

Masatoshi Kudo et al.

Summary: Nivolumab monotherapy showed clinical activity and favorable safety in patients with Child-Pugh B status aHCC, with manageable treatment-related adverse events, suggesting its suitability for this patient population.

JOURNAL OF HEPATOLOGY (2021)

添加到收藏夹

Article Oncology

Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study

Zhenggang Ren et al.

Summary: The study aimed to assess the efficacy of sintilimab plus IBI305 versus sorafenib as a first-line treatment for unresectable HBV-associated hepatocellular carcinoma in China, showing significant overall survival and progression-free survival benefits with acceptable safety profiles.

LANCET ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Neoadjuvant cabozantinib and nivolumab convert locally advanced hepatocellular carcinoma into resectable disease with enhanced antitumor immunity

Won Jin Ho et al.

Summary: A study evaluating neoadjuvant cabozantinib and nivolumab in patients with hepatocellular carcinoma (HCC) showed that 80% of patients successfully underwent hepatic resection surgery, with 42% having major pathological responses. An in-depth biospecimen profiling indicated an orchestrated contribution of B cells to antitumor immunity in HCC, with effector T cells, tertiary lymphoid structures, CD138(+) plasma cells, and a distinct spatial arrangement of B cells being enriched in responders compared to nonresponders.

NATURE CANCER (2021)

添加到收藏夹

Article Multidisciplinary Sciences

NASH limits anti-tumour surveillance in immunotherapy-treated HCC

Dominik Pfister et al.

Summary: The text discusses the impact of NASH on the development of HCC and the effect of immunotherapy, revealing the accumulation of exhausted and unconventionally activated CD8(+)PD1(+) T cells in NASH-affected livers. In preclinical models of NASH-induced HCC, anti-PD1 treatment led to an increase in HCC, with CD8(+) T cells contributing to this increase.

NATURE (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

National Experience on Down-Staging of Hepatocellular Carcinoma Before Liver Transplant: Influence of Tumor Burden, Alpha-Fetoprotein, and Wait Time

Neil Mehta et al.

HEPATOLOGY (2020)

添加到收藏夹

Article Gastroenterology & Hepatology

REFLECT-a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset

Tatsuya Yamashita et al.

JOURNAL OF GASTROENTEROLOGY (2020)

添加到收藏夹

Article Gastroenterology & Hepatology

Liver Transplantation Outcomes in a US Multicenter Cohort of 789 Patients With Hepatocellular Carcinoma Presenting Beyond Milan Criteria

Ani Kardashian et al.

HEPATOLOGY (2020)

添加到收藏夹

Article Oncology

Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial

Richard S. Finn et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Oncology

A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements

Masatoshi Kudo et al.

LIVER CANCER (2020)

添加到收藏夹

Article Medicine, General & Internal

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Richard S. Finn et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Oncology

Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b/3 trial

Vincenzo Mazzaferro et al.

LANCET ONCOLOGY (2020)

添加到收藏夹

Article Gastroenterology & Hepatology

Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial

Masatoshi Kudo et al.

GUT (2020)

添加到收藏夹

Review Immunology

Tumour-intrinsic resistance to immune checkpoint blockade

Anusha Kalbasi et al.

NATURE REVIEWS IMMUNOLOGY (2020)

添加到收藏夹

Article Surgery

Meta-analysis of short- and long-term outcomes after pure laparoscopic versus open liver surgery in hepatocellular carcinoma patients

Jan Witowski et al.

SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES (2019)

添加到收藏夹

Article Gastroenterology & Hepatology

Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection Is Associated With Increased Survival in Patients With a History of Hepatocellular Carcinoma

Amit G. Singal et al.

GASTROENTEROLOGY (2019)

添加到收藏夹

Article Gastroenterology & Hepatology

Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2017 (4th JSH-HCC guidelines) 2019 update

Norihiro Kokudo et al.

HEPATOLOGY RESEARCH (2019)

添加到收藏夹

Review Gastroenterology & Hepatology

Insights into the success and failure of systemic therapy for hepatocellular carcinoma

Jordi Bruix et al.

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2019)

添加到收藏夹

Article Oncology

Lenvatinib as an Initial Treatment in Patients with Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child-Pugh A Liver Function: A Proof-Of-Concept Study

Masatoshi Kudo et al.

CANCERS (2019)

添加到收藏夹

Article Gastroenterology & Hepatology

Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma

Jens Ricke et al.

JOURNAL OF HEPATOLOGY (2019)

添加到收藏夹

Review Oncology

A Systematic Review and Meta-Analysis Comparing the Short- and Long-Term Outcomes for Laparoscopic and Open Liver Resections for Hepatocellular Carcinoma: Updated Results from the European Guidelines Meeting on Laparoscopic Liver Surgery, Southampton, UK, 2017

Ruben Ciria et al.

ANNALS OF SURGICAL ONCOLOGY (2019)

添加到收藏夹

Article Gastroenterology & Hepatology

Direct-Acting Antiviral Therapy Not Associated With Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study

Amit G. Singal et al.

GASTROENTEROLOGY (2019)

添加到收藏夹

Article Gastroenterology & Hepatology

Alpha-Fetoprotein Decrease from > 1,000 to < 500 ng/mL in Patients with Hepatocellular Carcinoma Leads to Improved Posttransplant Outcomes

Neil Mehta et al.

HEPATOLOGY (2019)

添加到收藏夹

Article Gastroenterology & Hepatology

Live donor liver transplantation for patients with hepatocellular carcinoma offers increased survival vs. deceased donation

Nicolas Goldaracena et al.

JOURNAL OF HEPATOLOGY (2019)

添加到收藏夹

Article Oncology

Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial

Andrew X. Zhu et al.

LANCET ONCOLOGY (2019)

添加到收藏夹

Article Surgery

Defining the chance of cure after resection for hepatocellular carcinoma within and beyond the Barcelona Clinic Liver Cancer guidelines: A multi-institutional analysis of 1,010 patients

Diamantis I. Tsilimigras et al.

SURGERY (2019)

添加到收藏夹

Review Gastroenterology & Hepatology

Systematic review with meta-analysis: the critical role of dermatological events in patients with hepatocellular carcinoma treated with sorafenib

Alvaro Diaz-Gonzalez et al.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2019)

添加到收藏夹

Review Gastroenterology & Hepatology

Therapies for patients with hepatocellular carcinoma awaiting liver transplantation: A systematic review and meta-analysis

Laura Kulik et al.

HEPATOLOGY (2018)

添加到收藏夹

Article Gastroenterology & Hepatology

Metroticket 2.0 Model for Analysis of Competing Risks of Death After Liver Transplantation for Hepatocellular Carcinoma

Vincenzo Mazzaferro et al.

GASTROENTEROLOGY (2018)

添加到收藏夹

Article Gastroenterology & Hepatology

Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases

Jorge A. Marrero et al.

HEPATOLOGY (2018)

添加到收藏夹

Article Gastroenterology & Hepatology

Hepatic resection compared to chemoembolization in intermediate- to advanced-stage hepatocellular carcinoma: A meta-analysis of high-quality studies

Myung Han Hyun et al.

HEPATOLOGY (2018)

添加到收藏夹

Article Oncology

Radiofrequency Ablation Versus Stereotactic Body Radiotherapy for Localized Hepatocellular Carcinoma in Nonsurgically Managed Patients: Analysis of the National Cancer Database

Devalkumar J. Rajyaguru et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

添加到收藏夹

Article Oncology

SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma

Pierce K. H. Chow et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

添加到收藏夹

Review Gastroenterology & Hepatology

Percutaneous treatment of hepatocellular carcinoma: State of the art and innovations

Jean-Charles Nault et al.

JOURNAL OF HEPATOLOGY (2018)

添加到收藏夹

Article Gastroenterology & Hepatology

EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma

Peter R. Galle et al.

JOURNAL OF HEPATOLOGY (2018)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Effectiveness and cost of radiofrequency ablation and stereotactic body radiotherapy for treatment of early-stage hepatocellular carcinoma: An analysis of SEER-medicare

Neehar D. Parikh et al.

JOURNAL OF MEDICAL IMAGING AND RADIATION ONCOLOGY (2018)

添加到收藏夹

Article Medicine, General & Internal

Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan

Chung-Kwe Wang

JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION (2018)

添加到收藏夹

Article Medicine, General & Internal

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

Masatoshi Kudo et al.

LANCET (2018)

添加到收藏夹

Article Oncology

Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study

Lorenza Rimassa et al.

LANCET ONCOLOGY (2018)

添加到收藏夹

Article Gastroenterology & Hepatology

Pilot study of living donor liver transplantation for patients with hepatocellular carcinoma exceeding Milan Criteria (Barcelona Clinic Liver Cancer extended criteria)

Josep M. Llovet et al.

LIVER TRANSPLANTATION (2018)

添加到收藏夹

Article Medicine, General & Internal

Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma

G. K. Abou-Alfa et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Review Gastroenterology & Hepatology

Systematic review with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases

Jonathan G. Stine et al.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)

添加到收藏夹

Article Oncology

Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

A. Vogel et al.

ANNALS OF ONCOLOGY (2018)

添加到收藏夹

Article Gastroenterology & Hepatology

Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection

Anthony W. H. Chan et al.

JOURNAL OF HEPATOLOGY (2018)

添加到收藏夹

Article Gastroenterology & Hepatology

Stereotactic body radiotherapy vs. TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma. An intention-to-treat analysis

Gonzalo Sapisochin et al.

JOURNAL OF HEPATOLOGY (2017)

添加到收藏夹

Article Medicine, General & Internal

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

Jordi Bruix et al.

LANCET (2017)

添加到收藏夹

Article Oncology

Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial

Valerie Vilgrain et al.

LANCET ONCOLOGY (2017)

添加到收藏夹

Article Surgery

Impact of Pretransplant Bridging Locoregional Therapy for Patients With Hepatocellular Carcinoma Within Milan Criteria Undergoing Liver Transplantation Analysis of 3601 Patients From the US Multicenter HCC Transplant Consortium

Vatche G. Agopian et al.

ANNALS OF SURGERY (2017)

添加到收藏夹

Article Gastroenterology & Hepatology

The Extended Toronto Criteria for Liver Transplantation in Patients With Hepatocellular Carcinoma: A Prospective Validation Study

Gonzalo Sapisochin et al.

HEPATOLOGY (2016)

添加到收藏夹

Article Gastroenterology & Hepatology

Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion

Takashi Kokudo et al.

JOURNAL OF HEPATOLOGY (2016)

添加到收藏夹

Article Surgery

Hierarchic Interaction of Factors Associated With Liver Decompensation After Resection for Hepatocellular Carcinoma

Davide Citterio et al.

JAMA SURGERY (2016)

添加到收藏夹

Article Surgery

Recurrence of Hepatocellular Cancer After Resection Patterns, Treatments, and Prognosis

Parissa Tabrizian et al.

ANNALS OF SURGERY (2015)

添加到收藏夹

Review Gastroenterology & Hepatology

Portal Hypertension and the Outcome of Surgery for Hepatocellular Carcinoma in Compensated Cirrhosis: A Systematic Review and Meta-analysis

Annalisa Berzigotti et al.

HEPATOLOGY (2015)

添加到收藏夹

Article Oncology

Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial

Jordi Bruix et al.

LANCET ONCOLOGY (2015)

添加到收藏夹

Article Oncology

Establishment of a Multidisciplinary Hepatocellular Carcinoma Clinic is Associated with Improved Clinical Outcome

Adam C. Yopp et al.

ANNALS OF SURGICAL ONCOLOGY (2014)

添加到收藏夹

Article Medicine, General & Internal

Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib The EVOLVE-1 Randomized Clinical Trial

Andrew X. Zhu et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)

添加到收藏夹

Article Gastroenterology & Hepatology

Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib

Maria Reig et al.

JOURNAL OF HEPATOLOGY (2014)

添加到收藏夹

Review Gastroenterology & Hepatology

Re-evaluating transarterial chemoembolization for the treatment of Hepatocellular Carcinoma: Consensus recommendations and review by an International Expert Panel

Ann Lii Cheng et al.

LIVER INTERNATIONAL (2014)

添加到收藏夹

Review Oncology

Transarterial Chemoembolization Failure/Refractoriness: JSH-LCSGJ Criteria 2014 Update

Masatoshi Kudo et al.

ONCOLOGY (2014)

添加到收藏夹

Article Oncology

Efficacy of Sorafenib in Intermediate-Stage Hepatocellular Carcinoma Patients Refractory to Transarterial Chemoembolization

Sadahisa Ogasawara et al.

ONCOLOGY (2014)

添加到收藏夹

Article Oncology

Validation of the Criteria of Transcatheter Arterial Chemoembolization Failure or Refractoriness in Patients with Advanced Hepatocellular Carcinoma Proposed by the LCSGJ

Tadaaki Arizumi et al.

ONCOLOGY (2014)

添加到收藏夹

Article Surgery

Above 5 cm, Size Does Not Matter Anymore in Patients with Hepatocellular Carcinoma

Chetana Lim et al.

WORLD JOURNAL OF SURGERY (2014)

添加到收藏夹

Article Oncology

How to Define Transarterial Chemoembolization Failure or Refractoriness: A European Perspective

Jean-Luc Raoul et al.

LIVER CANCER (2014)

添加到收藏夹

Article Gastroenterology & Hepatology

Postprogression Survival of Patients With Advanced Hepatocellular Carcinoma: Rationale for Second-Line Trial Design

Maria Reig et al.

HEPATOLOGY (2013)

添加到收藏夹

Article Oncology

Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study

Josep M. Llovet et al.

JOURNAL OF CLINICAL ONCOLOGY (2013)

添加到收藏夹

Article Gastroenterology & Hepatology

Liver Transplantation for Hepatocellular Carcinoma: A Model Including α-Fetoprotein Improves the Performance of Milan Criteria

Christophe Duvoux et al.

GASTROENTEROLOGY (2012)

添加到收藏夹

Article Gastroenterology & Hepatology

Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design

Marta Burrel et al.

JOURNAL OF HEPATOLOGY (2012)

添加到收藏夹

Article Gastroenterology & Hepatology

Management of Hepatocellular Carcinoma in Japan: Consensus-Based Clinical Practice Guidelines Proposed by the Japan Society of Hepatology (JSH) 2010 Updated Version

Masatoshi Kudo et al.

DIGESTIVE DISEASES (2011)

添加到收藏夹

Article Gastroenterology & Hepatology

Clinical Decision Making and Research in Hepatocellular Carcinoma: Pivotal Role of Imaging Techniques

Jordi Bruix et al.

HEPATOLOGY (2011)

添加到收藏夹

Editorial Material Gastroenterology & Hepatology

Multifaceted Perspective of the Waiting List for Liver Transplantation: The Value of Pharmacokinetic Models

Miquel Navasa et al.

HEPATOLOGY (2010)

添加到收藏夹

Article Oncology

Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis

Vincenzo Mazzaferro et al.

LANCET ONCOLOGY (2009)

添加到收藏夹

Article Medicine, General & Internal

Sorafenib in advanced hepatocellular carcinoma

Josep M. Llovet et al.

NEW ENGLAND JOURNAL OF MEDICINE (2008)

添加到收藏夹

Article Surgery

Liver transplantation for hepatocellular carcinoma: Validation of the UCSF-Expanded criteria based on preoperative imaging

F. Y. Yao et al.

AMERICAN JOURNAL OF TRANSPLANTATION (2007)

添加到收藏夹

Article Oncology

Phase II study of sorafenib in patients with advanced hepatocellular carcinoma

Ghassan K. Abou-Alfa et al.

JOURNAL OF CLINICAL ONCOLOGY (2006)

添加到收藏夹

Review Gastroenterology & Hepatology

Management of hepatoceullular carcinoma

J Bruix et al.

HEPATOLOGY (2005)

添加到收藏夹

Article Gastroenterology & Hepatology

Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less

SM Lin et al.

GUT (2005)

添加到收藏夹

Article Gastroenterology & Hepatology

A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma

S Shiina et al.

GASTROENTEROLOGY (2005)

添加到收藏夹

Review Multidisciplinary Sciences

Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy

RK Jain

SCIENCE (2005)

添加到收藏夹

Article Radiology, Nuclear Medicine & Medical Imaging

Small hepatocellular carcinoma in cirrhosis: Randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection

RA Lencioni et al.

RADIOLOGY (2003)

添加到收藏夹

Breakthroughs in Hepatocellular Carcinoma Therapies

相关参考文献

导出引文

分享论文